ArticleOrphanet journal of rare diseases2026
Generation and characterization of a novel Gaa compound heterozygous mouse model recapitulating human Pompe disease.
Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPompe disease (PD), caused by a deficiency in acid α-glucosidase (GAA), is a lysosomal storage disorder. Existing Gaa knockout and point mutation mouse models have substantially advanced mechanistic understanding, but most are homozygous for single mutations and do not faithfully model the compound‑heterozygous GAA genotypes common in patients. A more clinically relevant in vivo model is still needed to enable systematic evaluation and faithful recapitulation of multi‑organ pathology. We previously reported an infantile-onset PD (IOPD) family carrying compound heterozygous GAA mutation (GAA c.1822 C > T/2662G > T; R608*/E888*). We here generated a novel compound heterozygous Gaa mouse model (Gaa c.1822 C > T/2665A > T; R608*/K889*), corresponding to human R608*/E888*), corresponding to human GAA identified in the IOPD family.
methodsCRISPR/Cas9-mediated knock-in introduced R608* (exon 14) and K889* (exon 18) mutations into C57BL/6 zygotes. Compound heterozygotes (CHet) were bred, validated via Sanger sequencing, and phenotyped using GAA activity assays, glycogen quantification, histopathology, transmission electron microscopy (TEM), and echocardiography. Parameters included cardiac structure/function, skeletal muscle integrity, hepatic glycogenosis, and diaphragmatic pathology.
resultsCHet mice exhibited reduced GAA activity and elevated plasma glycogen levels, recapitulating the metabolic hallmark of human PD. Systemic pathophysiological characterization revealed multi-organ dysfunction: the heart showed pronounced hypertrophy with structural remodeling, evidenced by thickened ventricular walls and sarcolemmal disarray, despite preserved compensatory function. Skeletal muscle pathology was marked by vacuolated myofibers, lysosomal glycogen accumulation, and mitochondrial abnormalities, reflecting impaired autophagic flux. Hepatic tissues displayed prominent glycogen storage, hepatocyte swelling, and disrupted cellular architecture. Diaphragmatic dysfunction, a critical determinant of respiratory failure in PD, was characterized by vacuolation, nuclear centralization, and inflammatory infiltration, with ultrastructural evidence of lysosomal glycogen deposition and mitochondrial damage across all tissues.
conclusionsTo our knowledge, this is among the first compound heterozygous Gaa mouse models integrating East Asian-specific GAA mutations (R608*/E888*) and demonstrating multi-organ pathophysiology similar to human PD. By preserving residual GAA activity (~ 18%) and recapitulating cardiac, skeletal, hepatic, and respiratory defects, our model provides an important complementary platform for elucidating mutation-specific mechanisms, optimizing enzyme replacement therapy (ERT), and advancing gene-editing strategies. Its alignment with patient-derived iPSC findings enhances the translational relevance of research in PD and lysosomal disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.